** Shares of therapy developer Trevi Therapeutics TRVI.O rise 21.9% to $5.24 premarket
** Co says its therapy, Haduvio, met the main goal in a mid-stage trial testing in patients with a type of chronic cough
** Says therapy showed statistically significant reduction in 24-hour cough frequency
** Currently, there are no approved treatments in the U.S. for coughing bouts that don't have no identifiable cause or those that persist despite treatment of underlying conditions
** GSK GSK.L has a chronic cough treatment in development, and Merck has an experimental drug for the disease which faced two FDA rejections in the past
** Up to last close, TRVI up 45.8% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.